Medibio Limited
MEB.AX
Australian Securities Exchange0.00
AUD
+0.00
- -
Medibio Limited
MEB.AX
(Australian Securities Exchange)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Medibio Limited (ASX:MEB), now operating as TrivarX Limited following a name change in October 2023, develops AI-driven, scientifically validated devices for the screening and diagnosis of behavioral health conditions, including depression and other mental illnesses, using objective biomarkers derived from brain and heart electrical signals; its lead product, MEB-001, analyzes data from standard sleep studies via single-channel electrocardiograms to detect current major depressive episodes with over 85% sensitivity, alongside corporate health solutions for mental well-being monitoring such as the LUCA app for stress management and ilumen platform for workforce performance optimization; and products targeting healthcare providers and consumers. The company, founded in 1987 and headquartered in Mount Lawley, Western Australia, with prior offices in South Melbourne, Melbourne, and U.S. locations including Minneapolis, Minnesota, primarily serves markets in Australia and the United States through clinical research, product development, and early-stage commercialization in the mental health technology sector. Recent developments include an extensive R&D program advancing the MEB-001 algorithm for improved sleep staging and depressive episode screening as of October 2025, alongside a 2023 ASX code transition to TRI reflecting the rebranding from former name BioProspect Limited, capital raisings such as $1.4 million in June 2022 and prior placements supporting FDA application progress, and director share issuances including 166 million shares to David Trimboli in June 2023; no major acquisitions, partnerships, or new product launches reported in 2024-2025.